The gold standard's flexible alloy: Adaptive designs on the advance

Annals of Emergency Medicine

Volumn 60, Issue 2, 2012, Pages A22-A27

  Millard, William B ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

NEUROPROTECTIVE AGENT; PLACEBO;

BAYES THEOREM; CLINICAL TRIAL (TOPIC); COMPUTER MODEL; EMERGENCY MEDICINE; GOLD STANDARD; HUMAN; MEDICAL SOCIETY; NEUROPROTECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIMULATION; STROKE; STUDY DESIGN; SYSTEMATIC ERROR;

EID: 84864230049     PISSN: 01960644     EISSN: 10976760     Source Type: Journal    
DOI: 10.1016/j.annemergmed.2012.06.001     Document Type: Review

References (13)

1. D. Reilly Cartoon New Yorker November 22, 1993 http://www.condenaststore. com/-sp/Hiram-S-Dudson-1930-1993-Member-Placebo-Group-New-Yorker-Cartoon-Prints- i8575160-.htm Accessed May 31, 2012
2. R.J. Lewis Adaptive clinical trials Presented at: UCLA Center for Maximizing Outcomes and Research Effectiveness, March 20, 2012, Los Angeles, CA http://cmore.med.ucla.edu/present/Adaptive Clinical Trials.Lewis.2012.pptx. Accessed May 31, 2012
3. M. Krams, K.R. Lees, W. Hacke Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): an adaptive dose-response study of UK-279,276 in acute ischemic stroke Stroke 34 2003 2543 2548 http://dx.doi.org/10.1161/01.STR. 0000092527.33910.89 Accessed May 31, 2012 (Pubitemid 37392736)
4. A.P. Grieve, M. Krams ASTIN: a bayesian adaptive dose-response trial in acute stroke Clin Trials 2 2005 340 351 discussion 352-358, 364-378 (Pubitemid 41306277)
5. D.A. Berry Adaptive clinical trials: the promise and the caution J Clin Oncol 29 2011 606 609 http://dx.doi.org/10.1200/JCO.2010.32.2685 http://jco.ascopubs.org/content/29/6/606.full Accessed June 1, 2012
6. S. Biswas, D.D. Liu, J.J. Lee Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center Clin Trials 6 2009 205 216 http://jco.ascopubs.org/content/29/6/606.full Accessed June 1, 2012
7. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER) Guidance for Industry: Adaptive Design Clinical Trials for Drugs and Biologics (Draft) 2010 Food and Drug Administration Silver Spring, MD http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM201790.pdf Accessed May 31, 2012
8. S. Beckett Worstward Ho 1983 John Calder London, England
9. S.-C. Chow, M. Chang Adaptive design methods in clinical trials: a review Orphanet J Rare Dis 3 2008 11 http://dx.doi.org/10.1186/1750-1172-3-11 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2422839/ Accessed June 18, 2012
10. W.J. Meurer, R.J. Lewis, D. Tagle An overview of the Adaptive Designs Accelerating Promising Trials Into Treatments (ADAPT-IT) project Ann Emerg Med 2012 http://dx.doi.org/10.1016/j.annemergmed.2012.01.020 http://www.annemergmed. com/article/S0196-0644%2812%2900110-2/fulltext
11. S.M. Berry, B.P. Carlin, J.J. Lee Bayesian Adaptive Methods for Clinical Trials 2011 CRC/Taylor & Francis Boca Raton, FL
12. A.D. Barker, C.C. Sigman, G.J. Kelloff I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy Clin Pharmacol Ther 86 2009 97 100
13. National Research Council Rare Diseases and Orphan Products: Accelerating Research and Development 2011 National Academies Press Washington, DC 77